Cargando…
Improved Anticancer Effect of Recombinant Protein izTRAIL Combined with Sorafenib and Peptide iRGD
One of the main problems in oncology is the development of drugs that cause the death of cancer cells without damaging normal cells. Another key problem to be solved is to suppress the drug resistance of cancer cells. The third important issue is to provide effective penetration of drug molecules to...
Autores principales: | Fadeev, Roman, Chekanov, Alexey, Solovieva, Marina, Bezborodova, Olga, Nemtsova, Elena, Dolgikh, Nadezda, Fadeeva, Irina, Senotov, Anatoly, Kobyakova, Margarita, Evstratova, Yana, Yakubovskaya, Raisa, Akatov, Vladimir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387460/ https://www.ncbi.nlm.nih.gov/pubmed/30691192 http://dx.doi.org/10.3390/ijms20030525 |
Ejemplares similares
-
Evaluation of CDK9 Inhibition by Dinaciclib in Combination with Apoptosis Modulating izTRAIL for the Treatment of Colorectal Cancer
por: Shen, Xiao, et al.
Publicado: (2023) -
Soft Biomimetic Approach for the Development of Calcinosis-Resistant Glutaraldehyde-Fixed Biomaterials for Cardiovascular Surgery
por: Zvyagina, Alyona I., et al.
Publicado: (2023) -
Macrophage-like THP-1 Cells Derived from High-Density Cell Culture Are Resistant to TRAIL-Induced Cell Death via Down-Regulation of Death-Receptors DR4 and DR5
por: Lomovskaya, Yana Vladimirovna, et al.
Publicado: (2022) -
The Increase in the Drug Resistance of Acute Myeloid Leukemia THP-1 Cells in High-Density Cell Culture Is Associated with Inflammatory-like Activation and Anti-Apoptotic Bcl-2 Proteins
por: Kobyakova, Margarita, et al.
Publicado: (2022) -
sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment
por: Huang, Ying, et al.
Publicado: (2017)